Pfizer antibody-drug conjugate Tivdak gains EMA panel endorsement

by
Contributor since / Followers
1 month ago
Concept image of an anticancer drug called ADC. 3d rendering

mesh cube

  • The European Medicine Agency’s Commitee for Medicinal Products for Human Use has issued a positive opinion on Pfizer’s (NYSE:PFE) antibody-drug conjugate Tivdak (tisotumab vedotin) for metastatic cervical cancer.
  • Pfizer has said that the treatment works “due to the binding of the
Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *